# US 2004/0062748 A1 · Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0062748 A1
- Document ID: US20040062748A1
- Status: Published application
- Kind: A1
- Application number: 10/317,092
- Filed: 2002-12-12
- Published: 2004-04-01
- Earliest claimed: 2002-09-30
- Assignees: Mountain View Pharmaceuticals, Inc.
- Inventors: Alexa L. Martinez; Merry R. Sherman; Mark G.P. Saifer; L. David Williams
- Web page: https://patentgrep.com/patent/US20040062748A1

## CPC

- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

## Claims

### Claim 1

A conjugate comprising one or more bioactive components covalently attached to at least one linear or branched polyalkylene glycol, wherein said polyalkylene glycol does not comprise an alkoxyl group at any terminus and said polyalkylene glycol is attached to a single bioactive component at a single site.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein said conjugate is reduced or substantially reduced in antigenicity compared to a conjugate comprising the same bioactive component(s) linked at the same site or sites to the same number of polyalkylene glycols of the same size and linear or branched structure containing one or more terminal alkoxyl groups.

### Claim 3 (depends on 1)

The conjugate of claim 1, wherein said linear or branched polyalkylene glycol is selected from the group consisting of a poly(ethylene glycol) and a copolymer of ethylene oxide and propylene oxide.

### Claim 4 (depends on 3)

The conjugate of claim 3, wherein said linear or branched polyalkylene glycol is a poly(ethylene glycol) (“PEG”).

### Claim 5 (depends on 1)

The conjugate of claim 1, wherein the attachment of said poly-alkylene glycol to said bioactive component(s) is carried out using a reactive derivative of at least one polyalkylene glycol selected from the group consisting of linear dihydroxyPEGs (“PEG diols”), hydroxyPEG-monoacetals and hydroxyPEG-monoacids.

### Claim 6 (depends on 1)

The conjugate of claim 1, wherein the attachment of said poly-alkylene glycol to said bioactive component(s) is carried out using a reactive derivative of hydroxyPEG selected from the group consisting of a monoaldehyde, a monoester of a monoacid, a monoamine, a monothiol, a monodisulfide, a monobromophenyl carbonate, a monochlorophenyl carbonate, a monofluorophenyl carbonate, a mononitrophenyl carbonate, a monocarbonylimidazole, a monohydrazide, a monoiodoacetamide, a monomaleimide, a monoorthopyridyl disulfide, a monooxime, a monophenyl glyoxal, a monothiazolidine-2-thione, a monothioester, a monotriazine and a monovinylsulfone.

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein said polyalkylene glycol has a molecular weight of from about 1,000 Daltons to about 100,000 Daltons (100 kDa).

### Claim 8 (depends on 7)

The conjugate of claim 7, wherein said polyalkylene glycol has a molecular weight of from about 2 kDa to about 60 kDa.

### Claim 9 (depends on 8)

The conjugate of claim 8, wherein said polyalkylene glycol has two branches, each with a molecular weight of from about 2 kDa to about 30 kDa.

### Claim 10 (depends on 9)

The conjugate of claim 9, wherein said polyalkylene glycol has two branches, each with a molecular weight of from about 5 kDa to about 20 kDa.

### Claim 11 (depends on 8)

The conjugate of claim 8, wherein said polyalkylene glycol has a molecular weight of from about 10 kDa to about 20 kDa.

### Claim 12 (depends on 11)

The conjugate of claim 11, wherein said polyalkylene glycol has a molecular weight of about 12 kDa.

### Claim 13 (depends on 8)

The conjugate of claim 8, wherein said polyalkylene glycol has a molecular weight of from about 18 kDa to about 60 kDa.

### Claim 14 (depends on 13)

The conjugate of claim 13, wherein said polyalkylene glycol has a molecular weight of from about 18 kDa to about 22 kDa.

### Claim 15 (depends on 14)

The conjugate of claim 14 wherein said polyalkylene glycol has a molecular weight of about 20 kDa.

### Claim 16 (depends on 13)

The conjugate of claim 13, wherein said polyalkylene glycol has a molecular weight of about 27 kDa to about 33 kDa.

### Claim 17 (depends on 1)

The conjugate of claim 1, wherein said conjugate comprises from about one to about 100 strands of said polyalkylene glycol.

### Claim 18 (depends on 17)

The conjugate of claim 17, wherein said conjugate comprises from about one to about five strands of said polyalkylene glycol.

### Claim 19 (depends on 18)

The conjugate of claim 18, wherein said conjugate comprises about one or about two strands of said polyalkylene glycol.

### Claim 20 (depends on 17)

The conjugate of claim 17, wherein said conjugate comprises from about five to about 100 strands of said polyalkylene glycol.

### Claim 21 (depends on 1)

The conjugate of claim 1, wherein said polyalkylene glycol is selected from the group consisting of a monohydroxyPEG-acid and a dihydroxyPEG-acid, such as dihydroxyPEG-lysine.

### Claim 22 (depends on 1)

The conjugate of claim 1, wherein said polyalkylene glycol, if linear, has a hydroxyl group at the terminus that is not attached to the bioactive component(s) (“the distal terminus”) or, if branched, has a hydroxyl group at every distal terminus.

### Claim 23 (depends on 5)

The conjugate of claim 5, wherein said polyalkylene glycol is a reactive derivative of said linear dihydroxyPEG.

### Claim 24 (depends on 5)

The conjugate of claim 5, wherein said polyalkylene glycol is a reactive derivative of said hydroxyPEG-monocarboxylic acid.

### Claim 25 (depends on 1)

The conjugate of claim 1, wherein said bioactive component is selected from the group consisting of a peptide, a protein, a glycoprotein, an organic compound, an amine-containing compound, a carboxyl-containing compound, a hydroxyl-containing compound and a thiol-containing compound.

### Claim 26 (depends on 25)

The conjugate of claim 25, wherein said bioactive component is selected from the group consisting of a peptide, a protein and a glycoprotein.

### Claim 27 (depends on 26)

The conjugate of claim 26, wherein said peptide or protein or glycoprotein is selected from the group consisting of an enzyme, a serum protein, a serum glycoprotein, a blood cell protein, a pigmentary protein, hemoglobin, a viral protein, a peptide hormone, a protein hormone, a glycoprotein hormone, a hypothalamic releasing factor, a cytokine, a growth factor and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing group.

### Claim 28 (depends on 27)

The conjugate of claim 27, wherein said serum protein is selected from the group consisting of an albumin, an immunoglobulin, a blood clotting factor and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing serum proteins.

### Claim 29 (depends on 27)

The conjugate of claim 27, wherein said peptide hormone or protein hormone or glycoprotein hormone is selected from the group consisting of an antidiuretic hormone, chorionic gonadotropin, luteinizing hormone, follicle-stimulating hormone, insulin, prolactin, a somatomedin, growth hormone, thyroid-stimulating hormone, a placental lactogen and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing hormones.

### Claim 30 (depends on 27)

The conjugate of claim 27, wherein said growth factor is selected from the group consisting of a colony-stimulating factor, an epidermal growth factor, a fibroblast growth factor, an insulin-like growth factor, a transforming growth factor, a platelet-derived growth factor, a nerve growth factor, a hepatocyte growth factor, a neurotrophic factor, a ciliary neurotrophic factor, a brain-derived neurotrophic factor, a glial-derived neurotrophic factor or a bone morphogenic peptide and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing growth factors.

### Claim 31 (depends on 27)

The conjugate of claim 27, wherein said cytokine is selected from the group consisting of erythropoietin, a lymphokine, an interleukin, an interferon, a tumor necrosis factor, a leukemia inhibitory factor and thrombopoietin, and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing cytokines.

### Claim 32 (depends on 27)

The conjugate of claim 27, wherein said enzyme is selected from the group consisting of a carbohydrate-specific enzyme, a proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase and a ligase.

### Claim 33 (depends on 32)

The conjugate of claim 32, wherein said oxidoreductase enzyme is a uricase.

### Claim 34 (depends on 32)

The conjugate of claim 32, wherein said proteolytic enzyme is a plasminogen activator.

### Claim 35 (depends on 26)

The conjugate of claim 26, wherein said peptide, protein or glycoprotein is an allergen.

### Claim 36 (depends on 1)

The conjugate of claim 1, wherein said bioactive compound is a taxane or a derivative thereof.

### Claim 37 (depends on 1)

The conjugate of claim 1, wherein said bioactive compound is an antibiotic or a derivative thereof.

### Claim 38 (depends on 1)

A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient or carrier.

### Claim 39 (depends on 1, 38)

A method of preventing, diagnosing, or treating a physical disorder in an animal, comprising the administration to said animal of an effective amount of the conjugate of claim 1 or the composition of claim 38.

### Claim 40 (depends on 39)

The method of claim 39, wherein said animal is a mammal.

### Claim 41 (depends on 40)

The method of claim 40, wherein said mammal is a human.

### Claim 42 (depends on 39)

The method of claim 39, wherein said physical disorder is selected from the group consisting of a cancer, arthritis, an infectious disease, a genetic disorder, a neurological disorder, a metabolic disorder, an enzymatic disorder, a cardiovascular disease and hypertension.

### Claim 43 (depends on 42)

The method of claim 42, wherein said cancer is selected from the group consisting of a breast cancer, a uterine cancer, an ovarian cancer, a prostate cancer, a testicular cancer, a lung cancer, a leukemia, a lymphoma, a colon cancer, a gastrointestinal cancer, a pancreatic cancer, a bladder cancer, a kidney cancer, a bone cancer, a neurological cancer, a head and neck cancer, a skin cancer and other carcinomas, sarcomas, adenomas and myelomas.

### Claim 44 (depends on 42)

The method of claim 42, wherein said infectious disease is selected from the group consisting of a bacterial disease, a fungal disease, a viral disease and a parasitic disease.

### Claim 45 (depends on 44)

The method of claim 44, wherein said viral disease is HIV/AIDS.

### Claim 46 (depends on 42)

The method of claim 42, wherein said genetic disorder is selected from the group consisting of amyotrophic lateral sclerosis, cystic fibrosis, Gaucher's disease, hemophilia and other inherited blood disorders, Pompe's disease and severe combined immunodeficiency disease (“SCID”).

### Claim 47 (depends on 42)

The method of claim 42, wherein said neurological disorder is Alzheimer's disease.

### Claim 48 (depends on 39)

The method of claim 39, wherein said administration is parenteral.

### Claim 49 (depends on 48)

The method of claim 48, wherein said parenteral administration is intravenous.

### Claim 50 (depends on 39)

The method of claim 39, wherein said administration is oral.

### Claim 51 (depends on 39)

The method of claim 39, wherein said administration is topical.

### Claim 52 (depends on 39)

The method of claim 39, wherein said administration is by inhalation.

### Claim 53 (depends on 39)

The method of claim 39, wherein said administration is rectal.

### Claim 54

A method of producing a conjugate between a bioactive compound and a polyalkylene glycol activated at only one terminus (“a monoactivated polyalkylene glycol”), comprising:
(a) obtaining a polyalkylene glycol that does not contain any end group that is a stably linked alkoxyl group;
(b) optionally, prior to the conversion of the polyalkylene glycol of step (a) to a monofunctionally activated polyalkylene glycol, protecting all except one of the end groups by the addition of one or more removable blocking groups, such as t-butoxyl group(s), aryloxyl group(s) or triphenylmethyl group(s) (“trityl group(s)”);
(c) producing a monofunctionally activated derivative of said polyalkylene glycol by reacting said polyalkylene glycol with a derivatizing compound or compounds under conditions such that said polyalkylene glycol is derivatized with a single derivatizing group at an end that does not contain said removable blocking group or groups;
(d) if a blocking group was added to protect the end group(s), as described in step (b) above, removing said blocking group, in one or more steps, without removing the activating group attached as described in step (c) above, to produce a monofunctionally activated polyalkylene glycol wherein the distal terminus or distal termini are hydroxyl groups; and
(e) contacting said monofunctionally activated polyalkylene glycol with at least one bioactive component, under conditions that favor the covalent binding of said monofunctionally activated polyalkylene glycol to said bioactive component, or
(f) Alternatively, performing step (e) prior to performing step (d).

### Claim 55 (depends on 54)

The method of claim 54, wherein said derivatizing group is selected from the group consisting of an aldehyde and a carboxyl group.

### Claim 56 (depends on 54)

The method of claim 54, wherein said blocking group is selected from the group consisting of a trityl group, an aryloxyl group and a t-butoxyl group.

### Claim 57

A method for separating a linear monohydroxyPEG-monoaldehyde from the corresponding PEG-dialdehyde comprising:
(a) converting all hydroxyl groups on the PEG-aldehyde to trityl derivatives;
(b) separating monotritylPEG-monoaldehyde from the PEG-dialdehyde and any ditritylPEG by reversed-phase chromatography, and
(c) converting the monotritylPEG-monoaldehyde to monohydroxyPEG-monoaldehyde by hydrolytic removal of the trityl group in an acidic medium.

### Claim 58 (depends on 57)

The method of claim 57, wherein said aldehyde is or said dialdehydes are in the form of acetal derivatives.

### Claim 59 (depends on 54)

A conjugate produced by the method of claim 54.

### Claim 60 (depends on 59)

The conjugate of claim 59, wherein said conjugate is reduced or substantially reduced in antigenicity compared to a conjugate comprising the same bioactive component linked at the same site or sites to the same number of molecules of polyalkylene glycol of the same size and linear or branched structure that contain an alkoxyl group at the distal terminus, if the polyalkylene glycol is linear, or contain two or more alkoxyl groups at the distal termini, if the polyalkylene glycol is branched.

### Claim 61 (depends on 59)

The conjugate of claim 59, wherein said polyalkylene glycol is selected from the group consisting of a poly(ethylene glycol) and a copolymer of ethylene oxide and propylene oxide.

### Claim 62 (depends on 59)

The conjugate of claim 59, wherein the polyalkylene glycol component is selected from the group consisting of a linear poly(ethylene glycol) and a branched poly(ethylene glycol).

### Claim 63 (depends on 59)

The conjugate of claim 59, wherein each said polyalkylene glycol has a molecular weight of from about 1 kDa to about 100 kDa.

### Claim 64 (depends on 63)

The conjugate of claim 63, wherein said polyalkylene glycol has a molecular weight of from about 2 kDa to about 60 kDa.

### Claim 65 (depends on 64)

The conjugate of claim 64, wherein said polyalkylene glycol has two branches, each with a molecular weight of from about 2 kDa to about 30 kDa.

### Claim 66 (depends on 65)

The conjugate of claim 65, wherein said polyalkylene glycol has two branches, each with a molecular weight of from about 5 kDa to about 20 kDa.

### Claim 67 (depends on 64)

The conjugate of claim 64, wherein said polyalkylene glycol has a molecular weight of from about 10 kDa to about 20 kDa.

### Claim 68 (depends on 67)

The conjugate of claim 67, wherein said polyalkylene glycol has a molecular weight of about 12 kDa.

### Claim 69 (depends on 64)

The conjugate of claim 64, wherein said polyalkylene glycol has a molecular weight of from about 18 kDa to about 60 kDa.

### Claim 70 (depends on 69)

The conjugate of claim 69, wherein said polyalkylene glycol has a molecular weight of from about 18 kDa to about 22 kDa.

### Claim 71 (depends on 70)

The conjugate of claim 70, wherein said polyalkylene glycol has a molecular weight of about 20 kDa.

### Claim 72 (depends on 69)

The conjugate of claim 69, wherein said polyalkylene glycol has a molecular weight of about 27 kDa to about 33 kDa.

### Claim 73 (depends on 59)

The conjugate of claim 59, wherein said conjugate comprises from one to about 100 strands of said polyalkylene glycol.

### Claim 74 (depends on 73)

The conjugate of claim 73, wherein said conjugate comprises from about one to about five strands of said polyalkylene glycol.

### Claim 75 (depends on 74)

The conjugate of claim 74, wherein said conjugate comprises about one or about two strands of said polyalkylene glycol.

### Claim 76 (depends on 73)

The conjugate of claim 73, wherein said conjugate comprises about five to about 100 strands of said polyalkylene glycol.

### Claim 77 (depends on 59)

The conjugate of claim 59, wherein the monofunctionally activated polyalkylene glycol used in the synthesis of said conjugate is selected from the group consisting of a hydroxyPEG-monoaldehyde and a reactive ester of a hydroxyPEG-monoacid.

### Claim 78 (depends on 59)

The conjugate of claim 59, wherein the monofunctionally activated polyalkylene glycol used in the synthesis of said conjugate has a hydroxyl group at its distal terminus, if it is linear, or has a hydroxyl group at every distal terminus, if it is branched.

### Claim 79 (depends on 59)

The conjugate of claim 59, wherein the monofunctionally activated polyalkylene glycol used in its synthesis is derived from a linear dihydroxyPEG.

### Claim 80 (depends on 59)

The conjugate of claim 59, wherein the bioactive component is selected from the group consisting of a peptide, a protein, a glycoprotein, an organic compound, an amine-containing compound, a carboxyl-containing compound, a hydroxyl-containing compound and a thiol-containing compound.

### Claim 81 (depends on 80)

The conjugate of claim 80, wherein said bioactive component is selected from the group consisting of a peptide, a protein and a glycoprotein.

### Claim 82 (depends on 81)

The conjugate of claim 81, wherein said peptide or protein or glycoprotein is selected from the group consisting of an enzyme, a serum protein, a serum glycoprotein, a blood cell protein, a pigmentary protein, hemoglobin, a viral protein, a peptide hormone, a protein hormone, a glycoprotein hormone, a hypothalamic releasing factor, a cytokine, a growth factor and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing group.

### Claim 83 (depends on 82)

The conjugate of claim 82, wherein said serum protein is selected from the group consisting of an albumin, an immunoglobulin, a blood-clotting factor and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing serum proteins.

### Claim 84 (depends on 82)

The conjugate of claim 82, wherein said peptide hormone or protein hormone or glycoprotein hormone is selected from the group consisting of an antidiuretic hormone, chorionic gonadotropin, luteinizing hormone, follicle-stimulating hormone, insulin, prolactin, a somatomedin, growth hormone, thyroid-stimulating hormone, a placental lactogen and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing hormones.

### Claim 85 (depends on 82)

The conjugate of claim 82, wherein said growth factor is selected from the group consisting of a colony-stimulating factor, an epidermal growth factor, a fibroblast growth factor, an insulin-like growth factor, a transforming growth factor, a platelet-derived growth factor, a nerve growth factor, a hepatocyte growth factor, a neurotrophic factor, a ciliary neurotrophic factor, a brain-derived neurotrophic factor, a glial-derived neurotrophic factor or a bone morphogenic peptide and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing growth factors.

### Claim 86 (depends on 82)

The conjugate of claim 82, wherein said cytokine is selected from the group consisting of erythropoietin, a lymphokine, an interleukin, an interferon, a tumor necrosis factor, a leukemia inhibitory factor and thrombopoietin, and peptides and proteins and glycoproteins that mimic or function as antagonists of any of the foregoing cytokines.

### Claim 87 (depends on 82)

The conjugate of claim 82, wherein said enzyme is selected from the group consisting of a carbohydrate-specific enzyme, a proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase and a ligase.

### Claim 88 (depends on 87)

The conjugate of claim 87, wherein said oxidoreductase enzyme is a uricase.

### Claim 89 (depends on 87)

The conjugate of claim 87, wherein said proteolytic enzyme is a plasminogen activator.

### Claim 90 (depends on 81)

The conjugate of claim 81, wherein said peptide, protein or glycoprotein is an allergen.

### Claim 91 (depends on 59)

The conjugate of claim 59, wherein the bioactive compound is a taxane or a derivative thereof.

### Claim 92 (depends on 59)

The conjugate of claim 59, wherein said bioactive compound is an antibiotic or a derivative thereof.

### Claim 93 (depends on 59)

A pharmaceutical composition comprising the conjugate of claim 59 and a pharmaceutically acceptable excipient or carrier.

### Claim 94 (depends on 1)

A kit comprising the conjugate of claim 1.

### Claim 95 (depends on 38)

A kit comprising the pharmaceutical composition of claim 38.

### Claim 96 (depends on 59)

A kit comprising the conjugate of claim 59.

### Claim 97

A PEG-liposome composition, wherein the PEG component does not comprise an alkoxyl group at any terminus and each molecule of PEG is attached to a single lipid molecule at a single site.

### Claim 98 (depends on 97)

The composition of claim 97, wherein said site of attachment is the amino group of a phosphatidyl ethanolamine.

### Claim 99 (depends on 97)

The composition of claim 97, wherein said site of attachment is the hydroxyl group of a diacylglycerol.

### Claim 100 (depends on 97)

The composition of claim 97, wherein said composition is reduced or substantially reduced in immunoreactivity compared to a PEG-liposome composition comprising at least one alkoxyPEG or a PEG that is attached to a lipid at more than one site or to more than one lipid molecule.
